Venetoclax (in combination with a hypomethylating agent) approved for use in EU for newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Approval was based on data from the Phase 3 VIALE-A trial, which found that those given venetoclax with azacitidine had improvements in overall survival vs those given azacitidine and placebo.

Source:

Biospace Inc.